Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEVANCE: Lenalidomide + Rituximab vs Chemotherapy in Untreated Follicular Lymphoma
NCT01476787Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2011
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of lenalidomide in follicular lymphoma (FL) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Complete Response Rate (CR/CRu) at 120 Weeks and Progression-free Survival at 140 months. Started Dec 2011; status: completed.
02
Drugs
lenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01476787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01476787.